In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae.
In COVID-19 clinical update #64, Daniel Griffin covers new guidance from NY on day camps, mitigation and infection rates in schools, testing to sustain in person instruction, Moderna mRNA vaccine highly effective in adolescents, longer storage of Pfizer vaccine, FDA EUA for sotrovimab, and persistent illness in UK children.
In COVID-19 clinical update #63, Daniel Griffin reviews cases at child care facilities, estimates of mRNA vaccine effectiveness, risk of reinfection in university students, enhanced antibody generation with extended interval of mRNA vaccination, no benefit of convalescent plasma in hospitalized patients, and risk of clinical sequelae after acute infection.
In COVID-19 clinical update #61, Daniel Griffin reviews a modeling of future hospitalizations and deaths by vaccination rates and non pharmaceutical intervention scenarios, performance evaluation of rapid antigen tests, children making up a growing share of new cases, antibody response to mRNA vaccine in solid organ transplant recipients, and outcomes in hospitalized patients treated with tocilizumab.
In COVID-19 clinical update #60, Daniel Griffin summarizes CDC guidance for summer camps, how to protect yourself when fully vaccinated, updated recommendation for J&J vaccine, declining global case fatality rate, and characterization of post-acute sequelae.
In COVID-19 clinical update #59, Daniel Griffin discusses a front-line health care worker survey, pre-exposure seropositivity and subsequent infection in healthy young adults, fitted filtration efficiency of double masking, BinaxNow rapid in-home antigen test, postvaccination infections in a nursing facility, safety of mRNA vaccine in pregnant women, case control study of Bamlanivimab, no evidence for brain infection in patients with neurolgical symptoms, and mortality among US patients hospitalized with COVID-19.
In COVID-19 clinical update #58, Daniel Griffin provides the latest update on the J&J vaccine pause, healthcare worker deaths, children and COVID, physical inactivity associated with higher risk, using monoclonal antibodies for prophylaxis, and shows us how to properly wear a face mask.
In COVID-19 clinical update #57, Daniel Griffin covers children and MIS-C, school opening plans, transmission event with masks, fomite transmission, diagnostic test performance, AZ vaccine and blood clots, and long COVID and the effect of vaccines.
Arturo Casadevall joins TWiV to discuss the use of convalescent plasma to treat COVID-19, including a history of the process, how plasma is prepared and tested, why it is difficult to conduct randomized clinical trials, how this treatment has fared and his hopes for the future.
In COVID-19 clinical update #56, Daniel Griffin notes increasing hospitalization in children and young adults, Pfizer vaccine efficacy results in 12-15 year olds, rapid self administered nucleic acid and antigen tests, mRNA vaccine efficacy in real world conditions, and improvement of long COVID after vaccination.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Rich Condit, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.